Publication | Open Access

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

HepatologyTransarterial ChemoembolisationMedicinePharmacologyPathologyLiver CancerCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaMolecular Oncology